Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine in type 2 diabetes mellitus
NCT02026232Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Mar 2012
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydroxychloroquine in type 2 diabetes mellitus (T2DM), sponsored by Washington University School of Medicine. Primary endpoint: Fasting Blood Glucose at 4 weeks. Started Mar 2012; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02026232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02026232.